/QTTB
QTTB Stock - Q32 Bio Inc.
Healthcare|BiotechnologyNASDAQ
$2.96-2.31%
$0.07 (-2.31%) • Dec 19
87
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.89
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1989.9%upside
Target: $61.86
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for QTTB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.93 – $2.99
TARGET (TP)$61.86
STOP LOSS$2.72
RISK/REWARD1:245.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.24
52W High$6.37
52W Low$1.34
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $-6,651,000 | $6.65M | $33.97M | $2.70M |
| Gross Profit | $-487,000 | $-6,651,000 | $6.65M | $24.43M | $2.70M |
| Gross Margin | N/A | 100.0% | 100.0% | 71.9% | 100.0% |
| Operating Income | $-66,102,000 | $-48,255,000 | $-39,225,000 | $-95,949,000 | $-130,263,000 |
| Net Income | $-47,733,000 | $-53,743,000 | $-42,809,000 | $-95,764,000 | $-128,694,000 |
| Net Margin | N/A | 808.0% | -643.6% | -281.9% | -4762.9% |
| EPS | $-5.12 | $-16.70 | $-13.42 | $-12.23 | $-50.46 |
Company Overview
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
1
11%
Buy / Outperform
5
56%
Hold / Neutral
3
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
6 Bullish3 Neutral/Bearish
Price Targets
$46
Average Target
↑ 1454.1% Upside
Now
$3
Low
$46
Average
$100
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 11th 2025 | BMO Capital Markets | Downgrade | Market Perform | $3← $22 |
| February 11th 2025 | Piper Sandler | Downgrade | Neutral | $4← $20 |
| December 11th 2024 | Guggenheim | Downgrade | Neutral | - |
| December 11th 2024 | Wells Fargo | Downgrade | Equal Weight | $16← $95 |
| December 11th 2024 | Raymond James | Downgrade | Outperform | $22← $90 |
| December 11th 2024 | Leerink Partners | Downgrade | Market Perform | $9← $68 |
| December 6th 2024 | BMO Capital Markets | Initiation | Outperform | $64 |
| October 24th 2024 | Raymond James | Initiation | Strong Buy | $90 |
| September 11th 2024 | Wells Fargo | Initiation | Overweight | $95 |
| June 17th 2024 | Guggenheim | Initiation | Buy | $100 |
| May 21st 2024 | Leerink Partners | Initiation | Outperform | $54 |
| April 11th 2024 | Oppenheimer | Initiation | Outperform | $50 |
| April 2nd 2024 | Piper Sandler | Initiation | Overweight | $45 |
Earnings History & Surprises
QTTBBeat Rate
47%
Last 15 quarters
Avg Surprise
-57.6%
EPS vs Estimate
Beats / Misses
7/8
Last 12 quarters
Latest EPS
$-0.60
Q4 2025
EPS Surprise History
Q1 24
+6.7%
$-0.28vs$-0.30
Q2 24
-826.1%
$-13.15vs$-1.42
Q3 24
-42.0%
$-1.42vs$-1.00
Q4 24
-3.5%
$-1.46vs$-1.41
Q1 25
+7.2%
$-1.16vs$-1.25
Q2 25
+26.8%
$-0.90vs$-1.23
Q3 25
+31.6%
$-0.78vs$-1.14
Q4 25
+56.8%
$-0.60vs$-1.39
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $-1.06 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-1.39 | $-0.60 | +56.8% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-1.14 | $-0.78 | +31.6% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-1.23 | $-0.90 | +26.8% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $-1.25 | $-1.16 | +7.2% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-1.41 | $-1.46 | -3.5% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-1.00 | $-1.42 | -42.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-1.42 | $-13.15 | -826.1% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | $-0.30 | $-0.28 | +6.7% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.42 | $-0.57 | -35.7% | ✗ MISS |
Q3 2023 | Jul 27, 2023 | $-8.55 | $-10.98 | -28.4% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-9.54 | $-9.00 | +5.7% | ✓ BEAT |
Q4 2022 | Dec 30, 2022 | $-8.86 | $-10.74 | -21.2% | ✗ MISS |
Q3 2022 | Sep 29, 2022 | $-8.21 | $-10.57 | -28.6% | ✗ MISS |
Q2 2022 | Jun 29, 2022 | $-9.68 | $-9.12 | +5.7% | ✓ BEAT |
Q1 2022 | Mar 30, 2022 | — | $28.65 | — | — |
Q4 2021 | Dec 30, 2021 | $-8.87 | $-10.58 | -19.3% | ✗ MISS |
Q3 2021 | Sep 29, 2021 | — | $-9.65 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-9.72 | — | — |
Latest News
Q32 Bio Mark Iwicki Withdraws Resignation From Q32 Bio Board; Mark Iwicki To Remain Chair Of Board
➖ NeutralBenzinga•Dec 19, 2025, 09:57 PM
Q32 Bio shares are trading higher after the company sold its Phase 2 complement inhibitor ADX-097 to Akebia for $12 million upfront and potential milestone and royalty payments up to $592 million.
📈 PositiveBenzinga•Dec 1, 2025, 12:54 PM•Also:
Market-Moving News for December 1st
➖ NeutralBenzinga•Dec 1, 2025, 12:37 PM•Also: ,
Akebia Therapeutics Establishes Rare Kidney Disease Pipeline With AKB-097 Acquisition From Q32 Bio And Praliciguat Candidate
📈 PositiveBenzinga•Dec 1, 2025, 12:09 PM•Also:
Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties
📈 PositiveBenzinga•Dec 1, 2025, 12:08 PM•Also:
Q32 Bio Q3 EPS $(0.60) Beats $(0.99) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 12:01 PM
Q32 Bio Completes Enrollment In Part B Of SIGNAL-AA Phase 2a Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA
📈 PositiveBenzinga•Oct 21, 2025, 11:13 AM
Frequently Asked Questions about QTTB
What is QTTB's current stock price?
Q32 Bio Inc. (QTTB) is currently trading at $2.96 per share. The stock has moved -2.31% today.
What is the analyst price target for QTTB?
The average analyst price target for QTTB is $61.86, based on 1 analyst.
What sector is Q32 Bio Inc. in?
Q32 Bio Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is QTTB's market cap?
Q32 Bio Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does QTTB pay dividends?
No, Q32 Bio Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
BOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
INTS
Intensity Therapeutics, Inc.
$0.41
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
PSTV
Plus Therapeutics, Inc.
$0.57
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
VRCA
Verrica Pharmaceuticals Inc.
$7.82
Mkt Cap: $0.1B
Explore stocks similar to QTTB for comparison